Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD
Status:
Unknown status
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the efficacy and safety of two different dosing regimens of
ranibizumab (0.5 mg on BCVA by 1+PRN vs 3+PRN) in Chinese patients with wet AMD. This study
is to provide long-term safety data in the treatment of Chinese patients with wet AMD.
Phase:
Phase 4
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Collaborators:
Eye & ENT Hospital of Fudan University Shanghai 10th People's Hospital Shanghai Zhongshan Hospital Xinhua Hospital, Shanghai Jiao Tong University School of Medicine